Atrium Therapeutics, Inc. (NasdaqGS: RNA)
Health Care · Biotechnology · US
$8.21
-2.26% today · -43.1% 1Y
Atrium Therapeutics, Inc. (NasdaqGS: RNA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $143.69M and employs 511 people.
Over the last twelve months the share price has lost 43.1%, trading between 7.63 and 16.77.
Tweenvest scores Atrium Therapeutics, Inc. across four factors: quality 25/100, value 65/100. Its strongest factor is value.
RNA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $143.69M
- Revenue (TTM)
- $35.84M
- P/E
- —
- EPS
- -3.86
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $16.77
- 52-week low
- $7.63
- Avg volume (3M)
- —
- Shares outstanding
- 17.11M
- Employees
- 511
- Next earnings
- —
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
- ISIN
- US04965N1046
- Founded
- 2025
- Listed since
- Feb 27, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| JW (Cayman) Therapeutics Co. LtdSEHK: 2126 | $146.12M | HK$2.83 | +5.21% |
| Acumen Pharmaceuticals, Inc.NasdaqGS: ABOS | $146.08M | $2.02 | -5.61% |
| CANbridge Pharmaceuticals Inc.SEHK: 1228 | $145.79M | HK$1.92 | -6.59% |
| Kangstem Biotech Co., Ltd.KOSDAQ: A217730 | $144.47M | ₩2,065.00 | -7.81% |
| UnicoCell Biomed Co., Ltd.TWSE: 6794 | $142.50M | NT$71.60 | -9.25% |
| Outlook Therapeutics, Inc.NasdaqCM: OTLK | $142.44M | $0.59 | -2.30% |
| Cloudbreak Pharma Inc.SEHK: 2592 | $140.32M | HK$— | — |
| Anavex Life Sciences Corp.NasdaqGS: AVXL | $139.97M | $1.51 | +1.34% |
Figures last refreshed Oct 11, 2026.